Published in final edited form as:

Org Lett. 2010 June 4; 12(11): 2610–2613. doi:10.1021/ol100819f.

Enantioselective Synthesis of (+)-Isolysergol *via* Ring Closing Metathesis

Jason A. Deck and Stephen F. Martin*

Department of Chemistry and Biochemistry, The University of Texas, Austin, Texas 78712.

Abstract

The first enantioselective synthesis of (+)-isolysergol was completed in 12 steps from commercially available materials by a novel approach that features a late stage microwave-mediated, diastereomeric ring closing metathesis catalyzed by a chiral molybdenum catalyst to simultaneously form the D ring and set the stereocenter at C(8).

The development of new and general strategies and tactics for the efficient synthesis of biologically important natural and unnatural substances is vital to advancing the science of organic chemistry. In this context, we were attracted some years ago to the potential of using ring closing metathesis (RCM)^{1,2} as a key construction for alkaloid synthesis,³ and we have applied such reactions to the syntheses of a number of alkaloids of varying complexity, including FR900482, manzamine A, (+)-anatoxin-a, and dihydrocorynantheol as well as other natural products.⁴

As part of an ongoing program to develop the utility and scope of RCM reactions, we became intrigued by the possibility of exploiting such a construction in the formulation of a novel synthetic approach to the tetracyclic ergot alkaloids. The ergot family of alkaloids has long attracted the interests of synthetic chemists, because of the varied and powerful biological activities of its members. Indeed, ergot alkaloids and their derivatives are widely used in the clinic, and there are numerous formulations containing natural or semi-synthetic ergot alkaloids for treating a diverse array of human maladies.⁵ Moreover, the challenges associated with preparing these alkaloids are legend, and despite numerous successful syntheses of lysergic acid and its derivatives,⁶ there are only two reported enantioselective syntheses,^{6k,n} one of which relied upon a late stage resolution.^{6k} There are, however, no syntheses that exercise complete regiochemical control of the $\Delta^{9,10}$ -double bond, the stereochemistry at C(8), and absolute stereochemistry. Thus, even though fifty years have passed since the first synthesis of lysergic acid, unsolved problems remain, despite a myriad of advances in synthetic methodology.

sfmartin@mail.utexas.edu.

Supporting Information Available. Experimental procedures, spectral data and copies of ¹H and ¹³C NMR spectra for all synthetic intermediates and 13. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Toward designing an enantioselective route to the lysergate group of alkaloids that addressed all of the stereo- and regiochemical control issues, we developed the plan outlined in Scheme 1. We envisioned that methyl lysergate (**1**) could be accessed from the advanced intermediate **2** by oxidative cleavage of the vinyl group at C(8) and deprotection of the indole nitrogen atom. The $\Delta^{9,10}$ -double bond in **2** would be formed regioselectively via an asymmetric ring closing metathesis (ARCM) reaction of **3**.⁷ This cyclization posed a significant challenge to existing technology as it mandated that the catalyst load selectively first onto one of the two diastereotopic vinyl groups prior to the RCM with the disubstituted exocyclic olefin. This process is to be contrasted with the usual sequence of ARCM reactions that presumably proceed by initial loading of the chiral catalyst onto the least hindered double bond of a triene, followed by selective cyclization involving one of the two enantiotopic olefins to deliver the chiral product, often with high enantioselectivity. Whether the desired cyclization of **3** would require a chiral catalyst to optimize the diastereoselectivity could only be addressed through experimentation. Indeed, the interesting questions surrounding cyclizations of substrates like **3** via ARCM processes provided a strong impetus for our efforts. The preparation of **3** would then require the *N*-alkylation of **4**, a reaction that was by no means certain. In earlier work we had prepared racemic **4** from the dehydro tryptophan derivative **5** by a sequence that featured a reductive Heck cyclization.⁸ Accordingly, access to **4** in enantiomerically pure form would require an enantioselective hydrogenation of **5**.

The known dehydroamino acid **5** was reduced with a *S,S*-DIPAMP modified rhodium catalyst to give a protected 4-bromotryptophan derivative in nearly quantitative yield and >90% enantioselectivity, thereby setting the absolute stereochemistry at C(5) (Scheme 2).⁹ Processing of the methyl ester into an acetylene moiety was achieved in a convenient, one-pot procedure according to a process we had previously developed that involved hydride reduction followed by reaction of the intermediate aldehyde with Ohira's reagent to give **6** (80% ee).^{3e}, 10 Despite considerable experimentation, we were unable to avoid some racemization during this process. Selective *N*-methylation of the carbamate moiety proceeded smoothly to give **7**. When *N*-methylation was performed on the intermediate protected amino acid ester, extensive racemization at C(5) was observed. Reductive Heck cyclization of **7** in the presence of 1,2,2,6,6-pentamethylpiperidine (PMP), followed by acid-catalyzed removal of the Boc protecting group gave **4** in 44% yield. This sequence was conducted without purification of the intermediate Heck product because the latter was contaminated with small quantities of the 7-membered ring product **8** together with other impurities that were difficult to remove.

At this juncture, it was necessary to convert **4** into the triene **3**. Preliminary attempts to introduce the branched dienyl group onto **4** via alkylation with 3-bromo-1,4-pentadiene, or similar amidation followed by selective reduction were unsuccessful. We eventually discovered, via extensive experimentation with reaction conditions and various pentadienyl organometallic agents, that reaction of the putative *N,O*-acetal derived from **4** with bispentadienylzinc provided **3** and **9** as an easily separable mixture (2:1) in 91% yield and 2:1 regioselectivity.¹¹

With triene **3** available, the key RCM was at hand. However, reaction of **3** with Grubbs I and II catalysts as well as Schrock's catalyst (**14**) either at room temperature or upon heating to 100 °C gave no isolable cyclization product. Similarly, analogs of **3** wherein the *N*-Me group had been exchanged for an *N*-Boc group or quaternized with iodomethane would not undergo metathesis. While it is well known that microwave heating can accelerate and improve the efficiency of transition metal mediated processes,¹² we are aware of no example of the use of microwave heating with molybdenum based metathesis catalysts. We were therefore delighted to find that heating **3** in the presence of **14** using microwave irradiation (300 W, 10 min) and forced air cooling did indeed induce a diastereoselective RCM to provide **10** and **2** in about 36 and 8% yields, respectively. The relative configurations of **10** and **2** were deduced via nOe correlations of protons on the D-ring and the pendant vinyl group relative to the proton of

known configuration at C(5) as shown. Because substrate-based control in the RCM led to the preferential formation of the undesired "iso" product **10**, we queried whether a chiral RCM catalyst might override this inherent diastereoselection and deliver increased amounts of **2**. Although no substrates of the complexity of **3** have been subjected to ARCM reactions, a review of the literature suggested that the Schrock-Hoveyda catalyst **15** might generate **2** as the major product. However, microwave heating (50 W, 30 min) of **3** in the presence of **15** again provided a mixture of **10** and **2**, but with improved yields of 55 and 20%, respectively. The antipodal Schrock-Hoveyda *ent*-**15** catalyst did not grant favoritism of **2** versus **10** and gave instead only trace amounts of **2** and **10**, presumably as a consequence of being mismatched. We also examined several other chiral molybdenum-derived catalysts that had been more recently developed by Hoveyda, but none of these led to improved levels of diastereoselectivity for either **10** or **2**.

Conversion of either **2** or **10** into methyl lysergate (**1**) or methyl isolysergate via oxidative cleavage of the vinyl group at C(8) proved to be an insurmountable challenge, a difficulty we attributed to the apparent instability of the intermediate aldehyde.¹⁴ After considerable experimentation, we discovered that the vinyl group in **10** could be cleaved by selective dihydroxylation of the terminal olefin, using a protocol reported by Donohoe, to give diols **11** as an inconsequential mixture (6.5:1) of diastereomers.¹⁵ Interestingly oxidation of a terminally monoprotected analog of **11**, to the presumed ketone, also gave only decomposition, further suggesting the instability of having an electron poor carbonyl (i.e. aldehyde or ketone not acid or amide) appended to C(8). Subsequent reaction of **11** with periodic acid in the presence of TFA, followed by immediate reduction of the unstable aldehyde thus produced with NaBH₃CN then furnished **12** in 83% yield. Removal of the tosyl protecting group from the indole nitrogen atom delivered (+)-isolysergol (**13**). Synthetic **13** displayed spectral characteristics (¹H NMR, ¹³C NMR, TLC, HPLC) identical with those in the literature, and with an authentic sample of racemic **13** provided by Professor Ohno.¹⁶ The ee of **13** thus obtained was determined to be 85% using chiral HPLC in comparison with racemic **13**.

In summary, we have completed the first enantioselective synthesis of isolysergol. The synthesis features a novel RCM, which was promoted by the chiral catalyst **15** using microwave heating, of the complex triene **3** bearing diastereotopic vinyl groups to give preferentially **10**, a cyclization that is enhanced through the agency of the chiral catalyst **15**. The synthesis requires a total of only 12 steps from commercially available 4-bromoindole. Other applications of olefin metathesis to solving problems in the total synthesis of complex natural products are under active investigation, and the results of these studies will be disclosed in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the National Institutes of Health (GM 25439), the Robert A. Welch Foundation, Pfizer, Inc., Merck Research Laboratories, and Boehringer Ingelheim Pharmaceuticals for their generous support of this research. We are also grateful to Dr. Richard Pederson (Materia, Inc.) for catalyst support, Professor Amir Hoveyda (Boston College) for generous gifts of chiral Mo-derived catalysts, and Professor Hiroaki Ohno (Graduate School of Pharmaceutical Sciences, Kyoto University) for providing a generous sample of synthetic, racemic isolysergol. J.A.D. would like to thank Dr. Kenner C. Rice (National Institute on Drug Abuse, National Institutes of Health) for helpful discussions and support during the final stages of the project.

References

1. For a general reviews of olefin metathesis and its applications, see: Grubbs, RH., editor. Handbook of Metathesis. Vol. Vol. 1–3. Wiley-VCH; 2003. .
2. For a general review of applications of RCM to the synthesis of oxygen and nitrogen heterocycles, see: Deiters A, Deiters SF. Chem. Rev 2004;104:2199–2238. [PubMed: 15137789] .
3. See for example: (a) Martin, SF. Handbook of Metathesis. Grubbs, RH., editor. Vol. Vol. 2. Wiley-VCH; 2003. p. 338–352. See also: (b) Martin SF, Liao Y, Wong Y, Rein T. Tetrahedron Lett 1994;35:691–694. (c) Martin SF, Liao Y, Chen H-J, Pätzelt M, Ramser MN. Tetrahedron Lett 1994;35:6005–6008. (d) Martin SF, Chen H-J, Courtney AK, Liao Y, Pätzelt M, Ramser MN, Wagman AS. Tetrahedron 1996;52:7251–7264. (e) Neipp CE, Martin SF. J. Org. Chem 2003;68:8867–8878. [PubMed: 14604356] (f) Simila STM, Martin SF. J. Org. Chem 2007;72:5342–5349. [PubMed: 17555359]
4. For selected references, see: (a) Fellows IM, Kaelin DE Jr, Martin SF. J. Am. Chem. Soc 2000;122:10781–10787. (b) Humphrey JM, Liao Y, Ali A, Rein T, Wong Y-L, Chen H-J, Courtney AK, Martin SF. J. Am. Chem. Soc 2002;124:8584–8592. [PubMed: 12121099] (c) Washburn DG, Heidebrecht RW Jr, Martin SF. Org. Lett 2003;5:3523–3525. [PubMed: 12967315] (d) Brenneman JB, Machauer R, Martin SF. Tetrahedron 2004;60:7301–7314. (e) Andrade RB, Martin SF. Org. Lett 2005;7:5733–5735. [PubMed: 16321034] (f) Deiters A, Pettersson M, Martin SF. J. Org. Chem 2006;71:6547–6561. [PubMed: 16901143] (g) Kummer DA, Brenneman JB, Martin SF. Tetrahedron 2006;62:11437–11449..
5. Mukherjee J, Menge M. Adv. Biochem. Eng. Biotechnol 2000;68:1–20. [PubMed: 11036684]
6. For selected syntheses of and approaches to lysergic acid, see: (a) Kornfield EC, Fornefeld EJ, Kline GB, Mann MJ, Morrison DE, Jones RG, Woodward RB. J. Am. Chem. Soc 1956;78:3087–3114. (b) Oppolzer W, Francotte E, Bättig K. Helv. Chim. Acta 1981;64:478–481. (c) Rebek J Jr, Tai DF, Shue Y-K. J. Am. Chem. Soc 1984;106:1813–1819. (d) Ninomiya I, Hashimoto C, Kiguchi T, Naito T. J. Chem. Soc., Perkin Trans. I 1985:941–948. (e) Cacchi S, Ciattini PG, Morera E, Ortar G. Tetrahedron Lett 1988;29:3117–3120. (f) Saá C, Crofts DD, Hsu G, Vollhardt KPC. Synlett 1994:487–489. (g) Özlü Y, Cladingboel DE, Parsons PJ. Tetrahedron 1994;50:2183–2206. (h) Barbey S, Mann J. Synlett 1995:27–28. (i) Marino JP Jr, Osterhout MH, Padwa A. J. Org. Chem 1995;60:2704–2713. (j) Ralbovsky JL, Scola PM, Sugino E, Burgos-Garcia C, Weinreb SM, Parvez M. Heterocycles 1996;43:1497–1512. (k) Moldvai I, Temesvári-Major E, Incze M, Szentirmay É, Gács-Baitz E, Szántay C. J. Org. Chem 2004;69:5993–6000. [PubMed: 15373483] (l) Hendrickson JB, Wang J. Org. Lett 2004;6:3–5. [PubMed: 14703336] (m) Inoue T, Yokoshima S, Fukuyama T. Heterocycles 2009;79:373–378. (n) Kurokawa T, Isomura M, Tokuyama H, Fukuyama T. SynLett 2009:775–777..
7. For a review of ARCM, see: Schrock RR, Hoveyda AH. Angew. Chem. Int. Ed 2003;42:4592–4633..
8. Lee KL, Goh JB, Martin SF. Tetrahedron Lett 2001;42:1635–1638.
9. Yokoyama Y, Matsumoto T, Murakami Y. J. Org. Chem 1995;60:1486–1487.
10. Dickson HD, Smith SC, Hinkle KW. Tetrahedron Lett 2004;45:5597–5599.
11. For related additions, see: (a) Courtois G, Harama M, Miginiac P. J. Organomet. Chem 1981;218:275–298. (b) Alvaro G, Grepioni F, Grilli S, Maini L, Martelli G, Savoia D. Synthesis 2000:581–587..
12. For some recent leading references, see: (a) Michaut A, Boddaert T, Coquerel Y, Rodriguez J. Synthesis 2007:2867–2871. (b) Coquerel Y, Rodriguez J. Eur. J. Org. Chem 2008:1125–1132. (c) Nicks F, Borguet Y, Delfosse S, Bicchielli D, Delaude L, Sauvage X, Demonceau A. Aust. J. Chem 2009;62:184–207..
13. Alexander JB, La DS, Cefalo DR, Hoveyda AH, Schrock RR. J. Am. Chem. Soc 1998;120:4041–4042.
14. Lysergaldehyde has not been characterized, and the few reports dealing with it or derivatives thereof describe only difficulties in formation of the aldehyde. For examples, see: (a) Lin C-CL, Blair GE, Cassady JM, Gröger D, Maier W, Floss HG. J. Org. Chem 1973;38:2249–2251. [PubMed: 4709278] (b) Choong TC, Thompson BL, Shough HR. J. Pharm. Sci 1977;66:1340–1341. [PubMed: 903880] .
15. Donohoe TJ, Moore PR, Waring MJ. Tetrahedron Lett 1997;38:5027–5030.
16. (a) Ninomiya I, Hashimoto C, Kiguchi T, Naito T, Barton DHR, Lusinchi X, Milliet P. J. Chem. Soc. Perkin. Trans. I 1990:707–713. (b) Inuki S, Oishi S, Fujii N, Ohno H. Org. Lett 2008;10:5239–5242. [PubMed: 18956869]

Scheme 1.
Approach to Methyl Lysergate (**1**)

Scheme 2.
Assembly of the Carbon Framework

Scheme 3.
Setting up the ARCM

Scheme 4.
ARCM and Completion of the Synthesis of Isolysergol (**13**)